Therapeutics/Diagnostics News

Children diagnosed with celiac disease and treated through a statewide screening program experienced improvements in initially unrecognized symptoms and quality of life, as well as greater adherence to a gluten-free diet, research showed.

A pharmacy-based, multicomponent intervention program reduced proton pump inhibitor use overall and also when appropriate for gastroprotection, with little evidence of either clinical harms or benefits, according to a study in BMJ.

The 10-year interval between screening colonoscopies “could potentially be extended” to 15 years among patients without a family history of colorectal cancer and negative findings for CRC at the first colonoscopy, researchers reported.

In a Healio video exclusive, Megan Riehl, PsyD, AGAF, and Kate Scarlata, MPH, RDN, LDN, discuss their new book, “Mind Your Gut,” a comprehensive guide for treating irritable bowel syndrome from nutritional and behavioral perspectives.

DENVER — Prior studies have shown that many diseases are tied to the gut microbiome, including metabolic disorders such as obesity, according to Sahil Khanna, MBBS, MS, FACG, AGAF.

A young woman, newly diagnosed with inflammatory bowel disease, sits in your office.

Vonoprazan was noninferior to high-dose IV proton pump inhibitor therapy in preventing 30-day rebleeding among patients with high-risk peptic ulcer bleeding who had achieved endoscopic hemostasis, according to data.

The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in adult patients with moderate-to-severe Crohn’s disease following induction therapy via IV administration of the biologic.

Once-daily Rinvoq 45 mg provided “rapid relief” of stool frequency and abdominal pain score within the first week of induction therapy in patients with moderately to severely active Crohn’s disease, according to a data analysis.

In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses data he presented at the GUILD Conference, which show patients with inflammatory bowel disease are at increased risk for cardiovascular events, likely driven by inflammation.